This paper is a cost-benefit analysis critique of an analysis done of the economic impact of Medicaid pharmaceutical care services at four hospital-based primary care outpatient clinics in Baltimore, noting how the analysis was done, what conclusions were reached, the evidence offered, and how effective the analysis is in addressing the subject.
